SAN FRANCISCO, August 14, 2025 — ProSomnus Sleep Technologies (“the Company”), the leading nonCPAP Obstructive Sleep Apnea (OSA) therapy®, announced its inclusion on the prestigious Inc. 5000 list of fastest growing private companies in the USA. This is the fourth year that ProSomnus has earned a spot on the Inc. 5000 list. Persistent and robust organic demand for ProSomnus’s sleep apnea devices, as opposed to price increases or acquisitions, was the exclusive driver of growth. ProSomnus ranked #79 in Manufacturing and #102 in the San Francisco Bay Area.
The Inc. 5000 list offers a data-driven snapshot of the most successful businesses in the US. Past honorees include household names such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. This recognition underscores ProSomnus’s commitment to advancing patient care through precision-custom intraoral medical devices that closely track the anatomy and treatment plan for each individual patient. ProSomnus devices have demonstrated safe, effective and patient preferred outcomes in more than a dozen clinical trials.
“ProSomnus is honored to be recognized by Inc. for the fourth year,” said Len Liptak, Chief Executive Officer of ProSomnus Sleep Technologies. “This achievement mirrors the dedication of ProSomnus team members, inputs from leading healthcare providers, and the burgeoning preference for personalized, non-CPAP solutions for the one billion people worldwide who suffer from obstructive sleep apnea.”
This year’s Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years.
Inc. will celebrate the honorees at the 2025 Inc. 5000 Conference & Gala, taking place October 22–24 in Phoenix, AZ and the top 500 will be listed in the Fall issue of Inc. magazine.
Methodology
Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.
About Inc.
Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.
About ProSomnus Sleep Technologies
ProSomnus Sleep Technologies is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.